ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BVC Batm Advanced Communications Ld

19.04
0.00 (0.00%)
Last Updated: 15:14:08
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Batm Advanced Communications Ld LSE:BVC London Ordinary Share IL0010849045 ORD ILS0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 19.04 19.00 19.94 172,852 15:14:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Communications Services, Nec 116.12M 244k 0.0006 317.33 83.02M

BATM Advanced Communications Ld Interim Results (3602I)

30/08/2016 7:01am

UK Regulatory


Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Batm Advanced Communicat... Charts.

TIDMBVC

RNS Number : 3602I

BATM Advanced Communications Ld

30 August 2016

30 August 2016

BATM Advanced Communications Limited

("BATM" or the "Group")

Interim results for six months ended 30 June 2016

BATM Advanced Communications Limited (LSE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces its interim results for the six months ended 30 June 2016.

Financial Summary

   --   Group revenue of $45.1m (H1 2015: $47.6m) 
   --   Gross margin improved to 32.8% (H1 2015: 31.7%) 
   --   Cash in flow from operations of $0.1m (H1 2015: $0.5m out flow) 
   --   Adjusted operating loss* of $0.6m (H1 2015: $0.3m loss) 
   --   EBITDA of $0.3m (H1 2015: $0.6m) 
   --   Net loss reduced to $1.5m (H1 2015: $2.0m loss) 
   --   Reduced loss per share to 0.23c (H1 2015: 0.38c loss per share) 

-- As at 30 June 2016, the Group had cash and financial assets of $18.6m (31 December 2015: $23.8m)

* Adjusted to exclude amortisation of intangible assets

Operational Summary

Bio-Medical Division (57% of total revenues)

-- Blended gross margins for the whole of Bio-Medical division improved to 26% compared with 25% in H1 2015

   --     Diagnostics Unit 

o Revenues increased by 19.2% and adjusted operating profit increased by 300%

o Significantly increased number of customers as 325 diagnostic machines were sold (462 in the whole of 2015)

o 25% increase in production of reagents compared with H1 2015

o Adaltis' Chinese partner, Egens Biotechnology Company Ltd. ("Egens"), agreed to purchase approximately 5.5% of Adaltis' enlarged share capital for RMB20m (approximately $3m) valuing Adaltis at approximately $58m

   --     Pathogenic Waste Treatment and Sterilisation Unit 

o Pathogenic Waste Treatment and Sterilisation unit successfully executed on first significant contract for its biological waste solution developed for the biopharmaceutical industry, which was installed and is operating at a facility of Ceva Animal Health ("CEVA")

o Commenced first large installation of new solution for treating agricultural waste and on track for delivering to the customer, a major poultry farming company, for testing in Q3 2016

   --     Distribution Unit 

o Acquired Green Lab Hungary Engineering Ltd ("Green Lab"), a developer and distributor of analytical instruments, for $3.8m in cash to strengthen the Group's regional distribution network and expand the Group's ecologic activities

o Increase in volume of Abbott products being distributed, in Romania, and the Group commenced providing maintenance

Networking and Cyber Division (43% of total revenues)

-- Blended gross margin increased to 42% from 40% in H1 2015 resulting in move to break-even in H1 2016 compared with adjusted operating loss of $0.2m for H1 2015

      --     Networking Unit 

o Gained over 35 new customers (H1 2015: 15 new customers) that are purchasing from the Networking unit's comprehensive portfolio of solutions

o Successfully deployed a new high capacity Carrier Ethernet network for the Kenya Education Network ("KENET")

o Delivered project extension to Tier 1 network service provider in Southeast Asia with deployment of 10GE solution to expand customer's broadband capacity and enable compliance with latest industry standards

o CloudMetro (SDN & D-NFV) platform is gaining momentum with Communication Service Providers (CSPs) and dozens of proof-of-concept trials were conducted successfully, including with Tier 1 operators

   --    Cyber Unit 

o Awarded a significant contract as the leading supplier for an ICT solution combined with several cyber elements to a government defence department, worth approximately $4m over a period of up to three years

o Engaged in several proof-of-concept trials in multiple countries

Commenting on the results, Dr Zvi Marom, Chief Executive Officer of BATM, said: "We are pleased with the results in the first half as the Group capitalised on the foundations laid in 2015 for a sustainable recovery and growth. Specifically, the Group focused on re-investing in sales and marketing in the Bio-Medical division resulting in it increasing its footprint and gaining a broader customer base, particularly in the Diagnostics unit. For the Networking and Cyber division the focus remained on conducting proof-of-concept trials of our latest software with Tier 1 companies and government agencies whilst maintaining tight cost control resulting in the division returning to profit at the operating level compared with a loss in the equivalent period last year.

"Looking ahead, we are excited by the potential positive impact of the investment in our Diagnostics business where we have positioned ourselves to capture a significant portion of the growing Chinese diagnostics market. This, together with the sustained growth in the rest of the Diagnostics business, is expected to result in further revenue growth in the second half of the year. In addition, we expect the Green Lab acquisition to provide access to a larger number of markets for our ecologic solutions in the Pathogenic Waste Treatment and Sterilisation business, which should see increased sales in the second half of the year, as well as continue to boost the Distribution unit. As a result of this, and further expected orders in the Cyber business sustaining the recovery in the Networking and Cyber division, the Board looks to the future with confidence."

Enquiries:

 
 BATM Advanced Communications 
---------------------------------------  ----------------- 
 Dr Zvi Marom, Chief Executive Officer    +972 9866 2525 
---------------------------------------  ----------------- 
 Moti Nagar, Chief Financial Officer 
---------------------------------------  ----------------- 
 
 finnCap 
---------------------------------------  ----------------- 
 Stuart Andrews, Scott Mathieson          +44 20 7220 0500 
---------------------------------------  ----------------- 
 
 Shore Capital 
---------------------------------------  ----------------- 
 Mark Percy, Anita Ghanekar               +44 20 7408 4090 
---------------------------------------  ----------------- 
 
 Luther Pendragon 
---------------------------------------  ----------------- 
 Harry Chathli, Claire Norbury            +44 20 7618 9100 
---------------------------------------  ----------------- 
 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Operational Review

In the first half of the year, the performance of the underlying business was robust as both divisions made significant operational progress as new products and technologies continued to replace legacy products. Revenues for the first half of 2016 were $45.1m (H1 2015: $47.6m) and gross margin improved to 32.8% from 31.7% in H1 2015. Significantly, both divisions achieved milestones in targeting new areas that the Group had identified as growth markets. In addition, the Group was active in completing two corporate transactions in the Bio-Medical division.

The Bio-Medical division accounted for 57% of total Group revenues with the contribution from the Networking and Cyber division being 43%.

Bio-Medical Division

The Bio-Medical division is engaged in the research and development, production, marketing and distribution of medical products, primarily laboratory diagnostic equipment and sterilisation equipment. Sales for this division are primarily in Europe.

 
                       H1 2016   H1 2015   H2 2015   FY 2015 
--------------------  --------  --------  --------  -------- 
 Revenues              $25.8m    $26.5m    $26.2m    $52.7m 
--------------------  --------  --------  --------  -------- 
 Gross margin          26%       25%       25%       25% 
--------------------  --------  --------  --------  -------- 
 Adjusted operating 
  profit*              $0.0m     $0.2m     $0.2m     $0.4m 
--------------------  --------  --------  --------  -------- 
 

* Adjusted to exclude amortisation of intangible assets

In H1 2016, revenues in the Bio-Medical division were 2.6% lower than the equivalent period last year at $25.8m (H1 2015: $26.5m) mainly due to a reduction in revenues in the Pathogenic Waste Treatment and Sterilisation unit. The gross profit margin was higher in H1 2016 at 26% compared with 25% in H1 2015, mostly due to an increase in revenue (approximately 19% y-o-y) in the Diagnostics unit.

Distribution

The Distribution unit contributed approximately 68% of Bio-Medical division revenues in H1 2016 compared with 67% in H1 2015. Gross margin in H1 2016 increased to 26% compared with 22% in H1 2015. The Distribution unit generated higher adjusted operating profit sequentially of $0.7m for H1 2016 compared with an adjusted operating profit of $0.3m in H2 2015.

Revenue was broadly flat, however there was an increase in the volume of Abbott products being distributed, in Romania, and the relationship was expanded with the Group starting to provide maintenance to some Abbott products. Abbott is one of the top three vendors in this field in this territory and the distribution of its products carries a higher margin and the Group anticipates further growth with the client.

In January 2016, the Group acquired the entire issued and to be issued share capital of Green Lab Hungary Engineering Ltd ("Green Lab"), a Hungary-based developer and distributor of analytical instruments for environmental and industrial sectors, for a total consideration of $3.8m payable in cash over a three-year period. The Group expects the Distribution unit to benefit from the synergies with the Green Lab operations in Hungary and from Green Lab's extensive network. Since acquisition, the integration has progressed well, with Green Lab continuing to achieve a good level of sales and profitability.

Pathogenic Waste Treatment and Sterilisation

The Pathogenic Waste Treatment and Sterilisation unit accounted for 9% of the Bio-Medical division's revenues in H1 2016 compared with 14% of revenues in H1 2015, reflecting a reduction in revenues primarily as a result of lower sales of control systems and medical waste products. The unit continues to focus on the treatment of biological waste, based on unique patented technology. In its traditional business, the Group experienced an increase in OEM (Original Equipment Manufacturer) orders from the US.

During the period, the installation and operation of the first biological waste solution unit for the biopharma industry was completed for CEVA. This project is expected to grow to $1.2m following further orders for the CEVA's European and US-based production sites in H2 2016 and 2017.

During 2015, the unit launched a unique solution, based on its patented ISS technology, for agri-business, which treats waste from poultry and larger animals such as cattle, pigs and cows. Over the last year, the solution has been tested with the relevant regulatory authorities to confirm its uniqueness and efficiency. During the period, the Group made progress under its contracts awarded in the second half of last year. In particular, it commenced implementing the new ISS-based solution for a major poultry farming company, and is on track for delivery to the customer for testing in Q3 2016, when the Group expects to commence generating revenue under this contract

This unit is also benefitting from the initial synergies with Green Lab, and expects the acquisition to provide access to a larger number of markets for the ecologic solutions of the Pathogenic Waste Treatment and Sterilisation business, which should see increased sales in the second half of the year.

Diagnostics

The Diagnostics unit represented 23% of the Bio-Medical division's revenues in H1 2016 compared with 19% during the first half of 2015, reflecting an increase in revenues of 19.2%. The Diagnostics unit continued to achieve a high margin of 32.4% and contributed a higher adjusted operating profit compared with H1 2015.

The growth in revenues is due to an increase in sales of both instruments and reagents. During the six-month period the Group sold 325 instruments compared with 462 for the full twelve months of 2015. The customer base has also broadened as a significant proportion of the instruments sold in 2015 were under a single contract. In addition, production of reagents increased 25% in H1 2016 over the same period of the prior year.

In December 2015, BATM entered into an agreement with Gamida for Life ("Gamida"), an international group of companies focused on healthcare and life sciences, to establish a joint venture company, Ador, to progress the development and marketing of a unique, rapid-results molecular diagnostics system. During the first half of 2016, progress was made on preparing for the production and marketing of the new instrument, and a selection of reagent kits, which are expected to reach the market during H2 2016.

As announced on 30 June 2016, a significant milestone was achieved when the Diagnostics unit entered into an investment agreement and a strategic joint venture with its Chinese partner, Egens Biotechnology Company Ltd. ("Egens"), a leading biotechnology company combining biological material development and diagnostic reagent manufacturing. Under the terms of the agreement, Egens purchased RMB20m (approximately $3m) of new shares in Adaltis, equivalent to approximately 5.5% of Adaltis' enlarged share capital, valuing Adaltis at approximately $58m. The joint venture company, Adaltis Bio Med Company ("ABC"), is already making significant progress and is expected to make a material contribution to revenues in H2 2016.

Networking and Cyber Division

The Networking and Cyber division is mostly engaged in the research and development, production and marketing of data communication products in the field of local and wide area networks and premises management systems. Sales for this division are global.

 
                       H1 2016   H1 2015   H2 2015   FY 2015 
--------------------  --------  --------  --------  -------- 
 Revenues              $19.1m    $20.9m    $23.2m    $44.1m 
--------------------  --------  --------  --------  -------- 
 Gross margin          42%       40%       40%       40% 
--------------------  --------  --------  --------  -------- 
 Adjusted operating 
  profit (loss)*       $0.0m     $(0.2m)   0.3m      $0.1m 
--------------------  --------  --------  --------  -------- 
 

* Adjusted to exclude amortisation of intangible assets

In H1 2016, there was a $1.8m decrease in revenues to $19.1m as the division continued to wind down the legacy products business whilst gaining traction with new products and solutions. Gross profit margin improved to 42% in H1 2016 compared with 40% in H1 2015.

Adjusted operating profit was break-even in H1 2016 compared with an adjusted operating loss of $0.2m for H1 2015.

Telco Systems gained over 35 new customers in the period compared with 15 new customers in H1 2015. This included the successful deployment of a new high capacity Carrier Ethernet network for the Kenya Education Network ("KENET").

Telco Systems continued to invest in its leading-edge technology and solutions and added 100GE capabilities to its new aggregation and ATCA solutions to meet the ever-increasing demand for bandwidth. During the period, it completed a project extension to a Tier 1 network service provider in Southeast Asia with the deployment of a 10GE solution to expand the customer's broadband capacity in compliance with latest industry standards. In addition, its CloudMetro (SDN & D-NFV) platform is gaining momentum with Communication Service Providers (CSPs) and dozens of proof-of-concept trials were conducted successfully, including with Tier 1 operators.

The Cyber unit was awarded a significant contract as the leading supplier for the delivery of an Information Communication Technology solution combined with several cyber elements to a government defence department. This contract is the second such contract awarded to BATM by a national government and is worth approximately $4m over a period of up to three years. The Cyber unit also conducted several proof-of-concept trials with Tier 1 companies and government agencies, which it expects to result in orders in the second half of the year.

The Group continues to maintain tight cost control in this division and reduced operating expenses by 8% compared with the same period last year.

Financial Review

Revenues in the first half of 2016 decreased by $2.5m to $45.1m (H1 2015: $47.6m). Bio-Medical division revenues decreased by 2.6% to $25.8m (H1 2015: $26.5m) whilst the Networking and Cyber division revenues decreased by 8.6% to $19.1m (H1 2015: $20.9m).

The blended gross profit margin for the first half of 2016 was 32.8% (H1 2015: 31.7%). This increase is mostly due to the increased contribution to revenue from the Diagnostics unit and an improvement in gross margin in the Networking and Cyber division.

Sales and marketing expenses were $7.3m (H1 2015: $7.3m), representing 16% of revenue compared with 15% in the first half of 2015.

General and administrative expenses were $4.7m (H1 2015: $5.0m), representing a decrease of 6% compared with the same period last year.

Research and development investment in the first half of 2016 decreased to $3.4m (H1 2015: $3.5m).

Net finance expense was $0.4m (H1 2015: $0.8m). The decrease is mainly due to the adverse effect of foreign exchange rate fluctuations.

Net loss after tax attributable to equity holders of the parent amounted to $0.9m (H1 2015: $1.5m), resulting in a basic loss per share of 0.23c (H1 2015: 0.38c).

The Group's balance sheet remains strong with effective liquidity of $18.6m compared with $23.8m as at 31 December 2015. Period-end cash is comprised as follows: cash and deposits up to three months duration of $16.1m and short-term cash deposits up to one year of $2.5m. The decline in cash balances is mainly due to the payment of $1.9m representing the initial portion of the consideration for the acquisition of Green Lab; purchase of property, plant and equipment of $1.7m, mainly in the sterilisation business; and a change in working capital.

Inventories decreased to $20.9m (31 December 2015: $22.6m). The decrease is mainly due to a lower level of inventory due to seasonality in the Distribution unit.

Trade and other receivables decreased to $28.1m from $31.2m at the end of 2015 mostly due to a decrease in trade receivable in the Networking and Cyber division.

Intangible assets and goodwill increased to $20.2m (31 December 2015 $15.6m). This increase is mostly due to the investment in Green Lab.

Property, plant and equipment increased to $19.4m (31 December 2015: $18.1m). This increase is due to the purchase of property, plant and equipment mainly in the sterilisation business.

The balance of trade and other payables decreased to $22.6m (31 December 2015: $27.4m). The decrease is mostly due to a decrease in the levels of inventory in the Distribution unit.

Cash inflow from operations was $0.1m for the first half of 2016 compared with an outflow of $0.5m for the first half of the prior year.

Outlook

The momentum achieved in the first half in the Bio-Medical division has continued into the second half of the year led by sustained growth in the Diagnostics unit. The Diagnostic unit's joint venture company, Adaltis Bio Med Company, is already making good progress in China and is expected to make a material contribution to revenues in H2 2016. This, in addition to the already growing diagnostics business, is expected to result in further acceleration in the second half of the year. In the Pathogenic Waste Treatment and Sterilisation business unit, the Group expects the Green Lab acquisition to provide access to a larger number of markets, which it anticipates will lead to increased sales.

The Networking and Cyber division continues to make progress in its recovery. The management team are focused on maintaining tight cost control in this division whilst continuing to drive the business forward. Several customers are testing its new SDN and NFV networking solutions, and the Group anticipates receiving orders later this year. The division's Cyber unit continues to experience increased interest from government agencies and corporations for its solutions and anticipates winning additional contracts in the second half of the year. As a result of growth in the Diagnostics unit and continued recovery in the Networking and Cyber division, the Board looks to the future with increased confidence.

BATM ADVANCED COMMUNICATIONS LTD.

CONSOLIDATED INCOME STATEMENTS

 
                                                         Six months ended 30 
                                                                 June 
                                                     2 0 1 6                   2015 
                                                          US$ in thousands 
                                                   Unaudited              Unaudited 
 
 Revenues                                             45,122                 47,566 
 
 Cost of revenues                                     30,340                 32,482 
 
 Gross profit                                         14,782                 15,084 
                                             ---------------        --------------- 
 Operating expenses 
 
    Sales and marketing expenses                       7,305                  7,259 
 
    General and administrative expenses                4,710                  4,959 
 
    Research and development expenses                  3,394                  3,476 
 
    Other operating expenses                             545                    442 
 
 Total operating expenses                             15,954                 16,136 
                                             ---------------        --------------- 
 Operating loss                                      (1,172)                (1,052) 
 
    Finance income                                       125                    103 
    Finance expenses                                   (513)                  (920) 
 
    Loss before tax                                  (1,560)                (1,869) 
 
    Income tax                                            27                  (102) 
 
 Loss for the period                                 (1,533)                (1,971) 
 
 Attributable to: 
    Owners of the Company                              (935)                (1,543) 
    Non-controlling interests                          (598)                  (428) 
 
 Loss for the period                                 (1,533)                (1,971) 
 Profit (loss) per share (In cents): 
 From continuing 
  and discontinued operations 
  Basic and Diluted                                   (0.23)                 (0.38) 
 
 From continuing operations 
  Basic and Diluted                                   (0.23)                 (0.38) 
 
 
 

BATM ADVANCED COMMUNICATIONS LTD.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

 
                                                           Six months ended 30 
                                                                   June 
                                                        2 0 1 6           2 0 15 
                                                             US$ in thousands 
                                                      Unaudited        Unaudited 
 
  Loss for the period                                   (1,533)          (1,971) 
  Items that may be reclassified subsequently 
   to profit or loss : 
 
  Exchange differences on translating foreign 
   operations                                               595          (2,797) 
  Total Comprehensive loss of the Period                  (938)          (4,768) 
  Attributable to: 
  Owners of the Company                                   (184)          (4,145) 
  Non-controlling interests                               (754)            (623) 
                                                          (938)          (4,768) 
 

BATM ADVANCED COMMUNICATIONS LTD.

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

 
                                               30 June                         30 June                     31 December 
                                               2 0 1 6                         2 0 1 5                         2 0 1 5 
                                                                              US$ in thousands 
                                             Unaudited                       Unaudited                         Audited 
 Current assets 
   Cash and cash 
    equivalents                                 16,112                          19,081                          17,042 
   Trade and other 
    receivables                                 28,067                          27,257                          31,180 
   Financial assets                              2,537                          11,159                           6,778 
   Inventories                                  20,894                          23,246                          22,630 
 
                                                67,610                          80,743                          77,630 
                        ------------------------------  ------------------------------  ------------------------------ 
 Non-current assets 
   Property, plant and 
    equipment                                   19,445                          19,417                          18,140 
   Investment property                           3,729                           2,542                           3,791 
   Goodwill                                     15,339                          11,611                          11,430 
   Other intangible 
    assets                                       4,841                           3,997                           4,168 
   Available for sale 
    Investments 
    carried at fair 
    value                                          614                           6,009                             611 
   Other assets                                      -                           5,041                               - 
   Deferred tax asset                            3,582                           5,937                           3,582 
                        ------------------------------  ------------------------------  ------------------------------ 
                                                47,550                          54,554                          41,722 
                        ------------------------------  ------------------------------  ------------------------------ 
 
 Total assets                                  115,160                         135,297                         119,352 
                        ==============================  ==============================  ============================== 
 Current liabilities 
   Short-term bank 
    credit                                       4,667                           3,978                           2,763 
   Trade and other 
    payables                                    22,576                          24,466                          27,442 
   Other liabilities                               633                           5,041                               - 
   Provisions                                      215                             242                             217 
                        ------------------------------  ------------------------------  ------------------------------ 
                                                28,091                          33,727                          30,422 
 Non-current 
 liabilities 
   Long-term 
    liabilities                                  5,729                           5,087                           6,636 
   Deferred tax 
    liabilities                                    997                           1,046                           1,095 
   Retirement benefit 
    obligation                                     738                             746                             707 
                                                 7,464                           6,879                           8,438 
 
 Total liabilities                              35,555                          40,606                      38,860 
 
   Equity 
   Share capital                                 1,216                           1,216                           1,216 
   Share premium 
    account                                    407,487                         407,367                         407,436 
   Foreign currency 
    translation 
    reserve and other 
    reserves                                  (19,637)                        (18,276)                        (20,388) 
   Accumulated deficit                       (307,249)                       (294,607)                       (306,314) 
                        ------------------------------  ------------------------------  ------------------------------ 
 Equity attributable 
 to equity 
 holders of the: 
   Owners of the 
    Company                                     81,817                          95,700                          81,950 
   Non-controlling 
    interest                                   (2,212)                         (1,009)                         (1,458) 
                        ==============================  ==============================  ============================== 
 Total equity                                   79,605                          94,691                          80,492 
                        ==============================  ==============================  ============================== 
 Total equity and 
  liabilities                                  115,160                         135,297                         119,352 
                        ==============================  ==============================  ============================== 
 

BATM ADVANCED COMMUNICATIONS LTD.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

Six months ended 30 June 2016

 
                             Share                                              Attributable   Non-Controlling 
                   Share     Premium    Translation    Other      Accumulated    to owners      Interests         Total 
                   Capital   Account    reserve        Reserve    Deficit        of the                           equity 
                                                                                 Parent 
                                                             US$ in thousands 
 As at 1 
  January 
  2016               1,216   407,436       (20,053)      (335)      (306,314)         81,950           (1,458)    80,492 
 Recognition 
  of 
  share-based 
  payments                        51                                                      51                          51 
 Loss for 
  the period                                                            (935)          (935)             (598)   (1,533) 
 Comprehensive 
  income (loss) 
  for the 
  period                                        751                         -            751             (156)       595 
 Total 
  comprehensive 
  loss for 
  the period                                    751                     (935)          (184)             (754)     (938) 
 As at 30 
  June 2016 
  (unaudited)        1,216   407,487       (19,302)      (335)      (307,249)         81,817           (2,212)    79,605 
 
 

Six months ended 30 June 2015

 
                             Share                                                Attributable   Non-Controlling 
                   Share      Premium     Translation    Other      Accumulated    to owners      Interests          Total 
                   Capital    Account     reserve        Reserve    Deficit        of the                            equity 
                                                                                   Parent 
                                                              US$ in thousands 
 As at 1 
  January 
  2015               1,216     407,345       (15,812)        138      (293,064)         99,823             (386)     99,437 
 Recognition 
  of 
  share-based 
  payments                          22                                                      22                           22 
 Loss for 
  the period                                                            (1,543)        (1,543)             (428)    (1,971) 
 Comprehensive 
  loss for 
  the period                                  (2,602)                         -        (2,602)             (195)    (2,797) 
 Total 
  comprehensive 
  loss for 
  the period                                  (2,602)                   (1,543)        (4,145)             (623)    (4,768) 
 As at 30 
  June 2015 
  (unaudited)        1,216     407,367       (18,414)        138      (294,607)         95,700           (1,009)     94,691 
 
 

BATM ADVANCED COMMUNICATIONS LTD.

CONSOLIDATED STATEMENT OF CASH FLOWS

 
                                                                                   Six months ended 30 June 
                                                                              2 0 1 6                          2 0 1 5 
                                                                                      US$ in thousands 
 
                                                                            Unaudited                        Unaudited 
 
 Net cash used in operating activities 
  (Appendix A)                                                                  (158)                          (3,601) 
                                                                    -----------------                ----------------- 
 Investing activities 
  Interest received                                                                91                               78 
  Proceeds on disposal of property, plant 
   and equipment                                                                   52                            1,409 
  Proceeds on disposal of deposits 
   Proceeds on disposal of financial assets                                     1,651                            9,750 
   carried at fair value through profit 
   and loss                                                                       525                                - 
  Proceeds on disposal of held to maturity                                      3,229                                - 
   investment 
  Purchases of property, plant and equipment                                  (1,731)                            (651) 
   Increase of other intangible assets                                        (1,192)                                - 
  Purchases of financial assets carried 
   at fair value 
   through profit and loss                                                          -                            (291) 
  Purchases of deposits 
   Purchase of financial assets carried 
   at fair value                                                              (1,151)                          (1,650) 
   through profit and loss 
   Acquisition of subsidiary (Appendix                                              -                          (1,709) 
   B)                                                                         (1,862)                                - 
  Net Cash outflow on acquisition of business 
   combinations                                                                     -                            (346) 
 Net cash from (used in) investing activities                                   (388)                            6,590 
                                                                    -----------------                ----------------- 
 Financing activities 
 
  Decrease in short-term bank credit                                              (2)                             (42) 
  Bank loan repayment                                                         (3,928)                          (1,822) 
  Bank loan received                                                            3,599                            2,222 
 Net cash from (used in) financing activities                                   (331)                              358 
                                                                     ----------------                ----------------- 
 Increase (decrease) in cash and cash 
  equivalents                                                                   (877)                            3,347 
 
 Cash and cash equivalents at the beginning 
  of the period                                                                17,042                           15,940 
 
  Effects of exchange rate changes on 
   the balance of cash held 
   in foreign currencies                                                         (53)                       (206) 
 
 Cash and cash equivalents at the end 
  of the period                                                                16,112                           19,081 
 
 
 

BATM ADVANCED COMMUNICATIONS LTD.

APPICES TO CONSOLIDATED STATEMENT OF CASH FLOWS

APPIX A

RECONCILIATION OF OPERATING LOSS FOR THE PERIOD TO NET CASH

USED IN OPERATING ACTIVITIES

 
                                                                      Six months ended 30 
                                                                              June 
                                                                    2 0 1 6             2 0 1 5 
                                                                        US$ in thousands 
                                                                 Unaudited            Unaudited 
 
 Operating loss from continuing operations 
 
  Adjustments for:                                                      (1,172)           (1,052) 
    Amortization of intangible assets                                       579               789 
    Depreciation of property, plant and equipment 
     and investment property                                                901               870 
    Capital gain of property, plant and equipment                             -             (490) 
    Stock options granted to employees                                       51                22 
    Increase (decrease) in retirement benefit obligation                     30              (40) 
    Decrease in provisions                                                  (2)              (76) 
 Operating cash flow before movements in working 
  capital                                                                   387                23 
     Decrease in inventory                                                1,821               956 
     Decrease in receivables                                              3,763             3,204 
     Decrease in payables                                               (5,864)           (1,614) 
     Effects of exchange rate changes on the balance 
      sheet                                                                (49)           (3,075) 
 Cash from (used in) operations                                              58             (506) 
    Income taxes paid                                                      (12)           (3,471) 
    Income taxes received                                                     -               649 
    Interest paid                                                         (204)             (273) 
 Net cash used in operating activities                                    (158)           (3,601) 
 
 

BATM ADVANCED COMMUNICATIONS LTD.

APPICES TO CONSOLIDATED STATEMENT OF CASH FLOWS

APPIX B

ACQUISITION OF SUBSIDIARY

GREEN LAB

 
 
                                                         2016 
                                             US$ in thousands 
                                                    Unaudited 
 Net assets acquired 
   Property, plant and equipment                          230 
   Inventory                                               85 
   Trade and other receivables                            645 
   Cash                                                    49 
   Trade payables and other liabilities                 (993) 
                                                           16 
   Goodwill                                             3,795 
 Total consideration                                    3,811 
 
   Satisfied by: 
   Cash                                                 1,911 
   Consideration recorded as liability                  1,900 
                                                        3,811 
 Net cash outflow arising on acquisition 
   Cash consideration                                   1,911 
   Cash and cash equivalents acquired                    (49) 
                                                        1,862 
 

BATM ADVANCED COMMUNICATIONS LTD

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 1 - Basis of preparation

The interim consolidated financial statements of the Company have been prepared in conformity with International Accounting Standard No. 34 "interim financial reporting" (hereafter "IAS 34").

In preparing these interim consolidated financial statements, the Company implemented accounting policies, presentation principles and calculation methods identical to those implemented in preparation of its consolidated financial statements as of 31 December 2015 and for the period ended on that date. The condensed interim financial statements should be read in conjunction with the annual financial statements for the year ended 31 December 2015, which have been prepared in accordance with IFRSs.

Note 2 - Profit/(loss) per share

Profit/(loss) per share is based on the weighted average number of shares in issue for the period of 403,150,820 (H1 2015: 403,150,820). The number used for the calculation of the diluted profit per share for the period (which includes the effect of dilutive stock option plans) is 403,150,820 shares (H1 2015 403,150,820).

Note 3 - Segments

Business Segment

 
                             Six months ended 30 June 2016 
 
                            Networking     Bio-Medical     Unallocated           Total 
                             and Cyber 
                                                US$ in thousands 
 Revenues                       19,137          25,800             185          45,122 
 
 Segment profit/(loss)              43               4           (674)           (627) 
 
 Reconciliation- 
  Other operating 
  expenses                                                                       (545) 
 
 Net Finance cost                                                                (388) 
 
 
 Loss before tax                                                               (1,560) 
 
 
 
                             Six months ended 30 June 2015 
 
                            Networking     Bio-Medical     Unallocated           Total 
                             and Cyber 
                                                 US$ in thousands 
 Revenues                       20,948          26,479             139          47,566 
 
 Segment profit/(loss)           (151)             240           (699)           (610) 
 
 Reconciliation- 
  Other operating 
  expenses                                                                       (442) 
 
 Net Finance cost                                                                (817) 
 
 
 Loss before tax                                                               (1,869) 
 
 

Note 4 - Financial instruments

The fair value of the financial instruments of the Group carried at amortised cost is not considered to be materially different from the amortised cost.

The following provides information of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Level 3 based on the degree to which their fair value is observable:

Level 3 fair value measurements are those derived from valuation techniques that include inputs for the liabilities that are not based on observable market data (unobservable inputs).

Financial liabilities-Government grants total amount: $3.5m

Note 5 - Investment in subsidiary: Green Lab

In January 2016, the Group acquired the entire issued and to be issued share capital of Green Lab Hungary Engineering Ltd ("Green Lab"), a Hungary-based developer and distributor of analytical instruments for environmental and industrial sectors, for a total consideration of $3.8m payable in cash over a three-year period.

The Company has not yet completed the purchase price allocation to the assets, liabilities and contingent liabilities of Green Lab and has temporarily classified the access cost as goodwill.

Note 6 - Non-cash transactions

The acquisition of Green Lab in the total consideration of $3.8m payable in cash over a three-year period comprising: $1.9m paid in cash on the acquisition date and $1.9m will be paid in three equal annual instalments and presented as non-cash transaction (Appendix B).

This information is provided by RNS

The company news service from the London Stock Exchange

END

IR SEEESUFMSELA

(END) Dow Jones Newswires

August 30, 2016 02:01 ET (06:01 GMT)

1 Year Batm Advanced Communicat... Chart

1 Year Batm Advanced Communicat... Chart

1 Month Batm Advanced Communicat... Chart

1 Month Batm Advanced Communicat... Chart

Your Recent History

Delayed Upgrade Clock